BridgeBio is substantially advanced the development of an novel therapy for cardiac amyloidosis, utilizing Attruby. Preliminary trial results indicates significant outcomes for individuals affected from the severe https://biotech023056.daneblogger.com/40760035/firm-progresses-cardiac-amyloidosis-management-using-the-drug